We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIteos Therapeutics Inc

Iteos Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-10-02T20:08:34.455836Z
Market Cap
616.98M

Momentum Score

…

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
8.20
Low
18.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
267.63M
Debt / Equity
0.01
ROE
-22.67%
Net Debt
-245.12M
ROCE
20.13%
Diluted EPS TTM
-3.65

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 148.74M 256.46M -38.09M -22.34M -18.05M
Net income 96.65M 214.52M -38.03M -22.45M -18.06M
Selling general administrative 43.95M 40.51M 15.34M 8.84M 4.31M
Gross profit 267.63M 344.77M - - -
Reconciled depreciation 0.80M 0.60M 0.54M 0.61M 0.51M
Ebit 126.32M 244.90M -45.24M -28.05M -17.98M
Ebitda 130.39M 255.69M -38.77M -21.72M -17.48M
Depreciation and amortization 4.07M 10.78M 6.47M 6.32M 0.51M
Non operating income net other 19.15M 1.38M -0.05M - -
Operating income 126.32M 244.90M -45.24M -28.05M -21.50M
Other operating expenses 138.04M 89.69M 39.31M 23.27M 17.82M
Interest expense -19.15M 1.38M 1.22M 0.00M 0.07M
Tax provision 52.08M 41.94M -0.06M 0.12M 0.01M
Interest income 11.36M - - - 0.07M
Net interest income 11.36M - - 0.00M -0.07M
Income tax expense 52.08M 41.94M -0.06M 0.12M 0.01M
Total revenue 267.63M 344.77M 0.00M 0.00M 0.00M
Total operating expenses 138.04M 89.69M 39.31M 23.27M 17.82M
Total other income expense net 22.41M 11.56M 7.15M 5.71M -0.16M
Net income from continuing ops 96.65M 214.52M -38.03M -22.45M -18.06M
Net income applicable to common shares 96.65M 214.52M -43.40M -26.54M -20.07M
Preferred stock and other adjustments - - 0.25M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 667.59M 754.99M 884.71M 344.56M 30.74M
Other current assets 12.24M 12.70M 24.17M 3.22M 0.88M
Total liab 92.36M 91.66M 331.89M 21.36M 15.07M
Total stockholder equity 575.23M 663.33M 552.82M 323.20M 15.67M
Other current liab 25.41M 19.73M 17.16M 7.49M 5.40M
Common stock 0.04M 0.04M 0.04M 0.04M 0.00M
Capital stock 0.04M 0.04M 0.04M 0.04M 51.76M
Retained earnings 124.63M 237.28M 140.62M -73.90M -35.87M
Other liab - 45.82M 23.20M 6.36M 1.88M
Other assets - 1.70M 2.60M 3.66M 3.33M
Cash 251.18M 284.80M 848.54M 336.33M 19.87M
Total current liabilities 40.01M 42.00M 304.12M 15.00M 13.20M
Current deferred revenue 2.06M 13.78M 281.05M 4.49M 2.36M
Net debt -245.12M -280.13M -843.20M -336.33M -19.87M
Short term debt 1.25M 0.84M 0.77M - 4.26M
Short long term debt total 6.06M 4.67M 5.34M - -
Other stockholder equity 463.80M 435.67M 413.18M 51.88M 53.61M
Property plant equipment - 2.12M 2.07M 1.35M 1.34M
Total current assets 550.65M 628.30M 874.71M 339.54M 26.08M
Long term investments 100.54M 118.22M - - -
Net tangible assets - 663.33M 552.82M 323.20M -36.09M
Short term investments 280.74M 328.36M - - -
Net receivables 6.50M 2.44M 12.09M 0.33M 5.33M
Inventory - - -10.09M -0.33M -
Accounts payable 11.29M 7.66M 5.14M 3.03M 1.17M
Accumulated other comprehensive income -13.24M -9.64M -1.02M 0.62M -0.22M
Common stock total equity - 0.04M 0.04M 0.04M 0.00M
Retained earnings total equity - 237.28M 140.62M -73.90M -
Non currrent assets other 5.67M 1.70M 2.60M 3.66M 3.33M
Non current assets total 116.94M 126.69M 10.00M 5.01M 4.67M
Capital lease obligations 6.06M 4.67M 5.34M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -445.00M -1.24M -0.38M -0.93M -0.30M
Change to liabilities -261.77M 293.37M 3.46M 1.82M -1.67M
Total cashflows from investing activities -446.06M -1.24M -0.38M -0.93M -0.30M
Net borrowings 1.06M 0.72M 4.05M - -
Total cash from financing activities 1.98M 3.66M 340.34M 22.54M 23.51M
Change to operating activities 29.87M 11.83M 5.87M -2.91M -1.27M
Net income 96.65M 214.52M -38.03M -22.45M -18.06M
Change in cash -563.80M 512.38M 316.46M -2.06M 3.24M
Begin period cash flow 848.84M 336.45M 19.99M 22.05M 18.82M
End period cash flow 285.04M 848.84M 336.45M 19.99M 22.05M
Total cash from operating activities -111.19M 513.14M -25.18M -23.14M -19.10M
Issuance of capital stock - 0.00M 339.02M 22.37M 23.56M
Depreciation 0.80M 0.60M 0.54M 0.61M 0.51M
Other cashflows from investing activities -0.12M -0.06M -0.02M -0.20M -0.07M
Change to inventory - - - - -1.27M
Change to account receivables - - 5.17M 0.00M 1.09M
Sale purchase of stock 0.93M 2.94M -0.33M 0.00M -0.23M
Other cashflows from financing activities 1.06M 3.66M 127.01M 22.54M 23.73M
Change to netincome 21.56M 13.79M 2.99M -0.22M 0.31M
Capital expenditures 0.94M 1.18M 0.36M 0.72M 0.23M
Cash flows other operating 31.56M -14.06M 3.59M - -
Exchange rate changes - -3.18M 1.68M - -
Cash and cash equivalents changes -555.27M 512.38M 316.46M - -
Change in working capital -228.49M 284.21M 9.33M -1.08M -1.86M
Stock based compensation 21.56M 13.79M 4.29M 0.81M 0.11M
Other non cash items -1.72M 0.01M -0.04M -0.01M 0.07M
Free cash flow -112.13M 511.96M -25.53M -23.87M -19.32M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Iteos Therapeutics Inc

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

321 Arsenal Street, Watertown, MA, United States, 02472

339 217 0161

https://www.iteostherapeutics.com

157

Name Title Year Born
Dr. Michel Detheux Ph.D. Pres, CEO & Director 1966
Mr. Matthew A. Call M.B.A. Chief Operating Officer 1973
Dr. Joanne Jenkins-Lager M.D. Chief Medical Officer 1972
Mr. Matthew Gall Chief Financial Officer 1977
Dr. Yvonne McGrath Ph.D. Chief Scientific Officer 1974
Mr. Ryan Baker Head of Investor Relations NA
Mr. Phillipe Brantegem Vice-Pres of HR NA
Dr. Michel Detheux Ph.D. President, CEO & Director 1967
Mr. Matthew Gall Chief Financial Officer 1978
Ms. Adi Osovsky VP & Head of Legal NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…